现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2014年
10期
2312-2314
,共3页
徐小峰%夏春伟%陈文萍
徐小峰%夏春偉%陳文萍
서소봉%하춘위%진문평
非小细胞肺癌%microRNA-99a%预后
非小細胞肺癌%microRNA-99a%預後
비소세포폐암%microRNA-99a%예후
NSCLC%microRNA-99a%prognosis
目的:探讨microRNA-99a在非小细胞肺癌( NSCLC)患者与正常人血清中的表达情况并分析其表达与临床病理特征及预后的关系。方法:收集70例非小细胞肺癌患者和60例正常人血清总RNA采用RT-PCR方法检测microRNA-99a的相对表达量,并分析其与临床病理资料和预后的相关性。结果:与正常人比较,血清microRNA-99a在非小细胞肺癌患者血清中表达下调,其表达与非小细胞肺癌患者的淋巴结转移、分化程度和TNM分期有显著相关性( P<0.05),非小细胞肺癌血清中microRNA-99a低表达者生存时间明显低于高表达者(P<0.05)。结论:非小细胞肺癌患者血清中microRNA-99a的表达下调与病情进展具有一定的相关性,可能作为肺癌治疗的新靶点。
目的:探討microRNA-99a在非小細胞肺癌( NSCLC)患者與正常人血清中的錶達情況併分析其錶達與臨床病理特徵及預後的關繫。方法:收集70例非小細胞肺癌患者和60例正常人血清總RNA採用RT-PCR方法檢測microRNA-99a的相對錶達量,併分析其與臨床病理資料和預後的相關性。結果:與正常人比較,血清microRNA-99a在非小細胞肺癌患者血清中錶達下調,其錶達與非小細胞肺癌患者的淋巴結轉移、分化程度和TNM分期有顯著相關性( P<0.05),非小細胞肺癌血清中microRNA-99a低錶達者生存時間明顯低于高錶達者(P<0.05)。結論:非小細胞肺癌患者血清中microRNA-99a的錶達下調與病情進展具有一定的相關性,可能作為肺癌治療的新靶點。
목적:탐토microRNA-99a재비소세포폐암( NSCLC)환자여정상인혈청중적표체정황병분석기표체여림상병리특정급예후적관계。방법:수집70례비소세포폐암환자화60례정상인혈청총RNA채용RT-PCR방법검측microRNA-99a적상대표체량,병분석기여림상병리자료화예후적상관성。결과:여정상인비교,혈청microRNA-99a재비소세포폐암환자혈청중표체하조,기표체여비소세포폐암환자적림파결전이、분화정도화TNM분기유현저상관성( P<0.05),비소세포폐암혈청중microRNA-99a저표체자생존시간명현저우고표체자(P<0.05)。결론:비소세포폐암환자혈청중microRNA-99a적표체하조여병정진전구유일정적상관성,가능작위폐암치료적신파점。
Objective:To investigate the expression of serum microRNA -99a in patients with NSCLC and in healthy people and to analyze the association of the expression with the cIinicopathologicaI features and prognosis. Methods:The expression levels of serum microRNA-99a in 70 patients with NSCLC and 60 healthy people were de-tected by using stem-loop real-time reverse transcription-polymerase chain reaction RT-PCR. Results:Expres-sion levels of microRNA-99a were downregulated in patients with NSCLC as compared with the healthy people(P<0. 05). The expression of microRNA-99a was associated with lymphatic metastasis,differentiation and TNM stages (P<0. 05). Low miR-99a expression was significantly correlated with overall survival(P<0. 05)of NSCLC. Con-clusion:The downregulation of serum microRNA-99a expression has relation with disease progression and microRNA-99a can serve as a potential therapeutic target for NSCLC.